Bay­er cuts four pro­grams amid a 's­low start' to the year

Bay­er an­nounced a hand­ful of pipeline cuts in its quar­ter­ly earn­ings re­port last week, as CEO Wern­er Bau­mann re­vealed the quar­ter “came in soft” com­pared to last year’s per­for­mance.

The culls in­clude two Phase II pro­grams, a BD­KRB1 re­cep­tor an­tag­o­nist for neu­ro­path­ic pain, and run­caciguat, in de­vel­op­ment for chron­ic kid­ney dis­ease. The BD­KRB1 re­cep­tor plays a role in pain per­cep­tion, and Bay­er’s can­di­date, BAY 2395840, came out of a re­search al­liance with Evotec. The com­pa­ny al­so said it’s dis­con­tin­u­ing a Phase I pro­gram study­ing BAY 2395840 in en­dometrio­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER